Szukaj
Współpraca badawcza (CZP)
Współpraca badawcza (CZP)
Togas Project - Towards Gastric Cancer Screening Implementation in the European Union – EU4Healt (HADEA)
https://www.europeancancer.org/eu-projects/resource/togas, No effective screening modality to prevent gastric cancer is available in Europe. Elimination of H. pylori bacteria is expected to decrease the mortality by 40%; another approach is early detection of precancerous lesions for surveillance.The TOGAS project aims at contributing to the improvement and fostering of health in the European Union by decreasing the burden, caused by gastric cancer. More precisely, TOGAS contributes to the Flagship 4 of the Europe’s Beating Cancer Plan: putting forward a new EU-Supported Cancer Screening Scheme, particularly, by developing novel approaches for screening and early detection of gastric cancer, and by providing options to extend screening for new cancers that are currently not included in the Recommendations of the European Council. The general objective of the TOGAS is to provide the missing evidence-based knowledge to be further transferred to design plan and implement appropriate gastric cancer prevention across the EU. The results from this project will help policy makers to incorporate gastric cancer screening into their healthcare priorities while balancing its effectiveness, feasibility and acceptability with long-term potential adverse effects.
URiCoV ERA PerMed (“PREVENTION IN PERSONALISED MEDICINE”) - URInary peptidomic patterns of Long-COVID syndrome "UriCoV"
https://erapermed.isciii.es/wp-content/uploads/2023/02/Newsletter-January-23_final1.pdf. Post acute sequelae of SARS-CoV-2 infection (PASC), also referred to as long COVID, is the most frequent, yet poorly characterized sequelae of COVID-19. It has tremendous, unpredictable consequences on personal health and socioeconomic status of affected individuals, and on global economic issues. UriCov is a multidisciplinary, comprehensive project with the aim to investigate in depth the molecular phenotype(s) of individual patients previously infected by SARS-CoV-2 and identify patients at risk of PASC. This will be achieved through multi-disciplinary research based on omics and clinical data in a bioinformatics framework, based on the hypothesis that endothelial damage is a key event in PASC. The developed molecular tools may allow patient stratification to initiate personalized treatment for prevention of PASC prior to symptoms and to decrease the PASC incidence. UriCoV will also provide missing fundamental knowledge on the molecular pathophysiology of PASC.
IntReALL 2020 - Grant agreement ID: 101104582 (Horizon Europe) - International Study for Treatment of Childhood Relapsed ALL 2020. Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of mortality in childhood cancer.
IntReALL 2020 will conduct randomized and historically controlled trials in children with relapsed B-cell precursor (BCP) ALL with the aim to replace toxic chemotherapy with better tolerated and more efficacious immunotherapeutic drugs. In standard risk (SR) patients, the CD22 directed antibody-drug conjugate inotuzumab ozogamicin (InO) will be randomly compared with standard of care (SOC) ALL-R3 induction. All patients will receive one SOC consolidation- and one Blina course, compared to historical controls. SR patients with MRD good response will receive 2 additional Blina courses replacing chemotherapy randomly compared with SOC. Patients with high-risk relapse will receive induction investigating InO versus ALL-R3 in an industry-sponsored trial, followed by IntReALL consolidation and allogeneic HSCT. Patients with isolated extramedullary (IEM) relapse are treated based on ALL-REZ BFM 2002 backbone. IntReALL 2020 will establish a federated relapsed/refractory leukaemia board generating personalized recommendations based on clinical, molecular-genetic and drug response profiling data. Patients with very-high risk disease will receive experimental/personalized therapies, including a trial investigating CD19-directed chimeric receptor antigen (CAR) T-cells produced in academic institutions. Other CAR T-cells trials as well as an induction trial for T-ALL relapse will be developed. Documentation and monitoring of the trials and the individualized treatment will be realized using the MARVIN database. Comprehensive statistical and data management activities will warrant the accuracy and interpretability of the data. IntReALL 2020 involves representatives from participating pharmaceutical companies and EMA as well as patient/parent advocates to discuss strategies for developing new drugs within academic trials warranting a benefit for all patients on the results. https://cordis.europa.eu/project/id/101104582
RECOMB - Stem-cell based gene therapy for recombination deficient SCID (RECOMB), Grant agreement ID: 755170 (Horizon2020)
Gene therapy for rare inherited immune disorders has become a clinical reality. Especially for SCID, two major types of SCID (ADA-SCID, X-SCID) have been successfully treated by autologous stem cell based gene therapy. However, for the most common group of SCID, the SCID underlying recombination defects, this has not yet occurred due to the higher complexities of the affected genes involved. The aim of the current proposal is to fill the unmet medical need for the most common major category of SCID, recombination activating gene-1 (RAG-1) deficient SCID, by performing Stage I/II clinical trials using autologous hematopoietic stem cell based gene therapy. To this end we will develop novel safety assays, pre-GMP and GMP lentiviral batches and design and conduct multicenter, multinational clinical trials with input from regulatory authorities such as EMA and patient advocacy groups. The trial will be conducted with phenotypic, molecular (integration sites, therapeutic gene expression) and functional readouts and should lead to effective treatment for > 70% of all SCID patients in Europe. RECOMB forms the logical extension of highly successful previous EU consortia that have made the EU global leader in gene therapy for orphan immune diseases. https://cordis.europa.eu/project/id/755170